Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy

Blue shape

You might also be interested in...

October 22, 2024

Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?

View

View

September 18, 2024

Tr1X to Participate at Upcoming Healthcare Investment Conferences

View

View

August 7, 2024

Tr1X Announces FDA Clearance of IND Application for TRX103, an Allogeneic Engineered Tr1 Treg Cell Therapy for Treatment-Refractory Crohn’s Disease.

View

View